Back to search results

Observational Study of MMA Embolization for Migraine

This study, EMBRACE-OBS, is looking at how Middle Meningeal Artery (MMA) embolization affects people with migraine. MMA embolization is a procedure already used in routine care for migraine. This study will collect information that doctors already gather from patients, like how often they get headaches, how severe they are, and how their quality of life changes after the procedure. It aims to understand if MMA embolization helps reduce headache frequency over time. You could join if you are an adult aged 18-64 with a migraine diagnosis who has had or plans to have MMA embolization as part of your regular medical care. The study will look for changes in your headache frequency at the start and again 12 months later. This is an observational study, meaning it won't change your medical care; it just collects information.

Study design
This is an observational study with 50 planned participants. It is not a randomized or blinded study.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants' headache frequency will be measured at the start of the study and again 12 months later.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07652034

EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine

Not Yet Recruiting
Not specifiedAges 18–64Observational
Cortex Neurovascular
~50 participants
Updated 2026-06-18 on ClinicalTrials.gov
What's tested:Middle Meningeal Artery Embolization

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Patient-Reported Headache Frequency
Measured over Baseline and 12 Months

Conditions

Migraine Disorders
Chronic Migraine Headache
Migraine

Explore related trials

Migraine

Where it's being run

1 sites across 1 states
Washington1

Who to contact

Dennis Wang, Principal Investigator, MD
[email protected]
253-284-0841
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults aged 18 to 64 years
Diagnosis of migraine
Have undergone or plan to undergo middle meningeal artery (MMA) embolization as part of routine clinical care, independent of study participation
Able and willing to provide informed consent
Able to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments

Exclusion

Age under 18 years
Pregnancy at the time of enrollment
Inability to provide informed consent
Inability to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments
Insufficient clinical or patient-reported outcome data for the planned analyses

What this trial measures

  • Change in Patient-Reported Headache FrequencyBaseline and 12 Months

    Change in patient-reported headache frequency, measured as headache days per month, from baseline to 12 months following middle meningeal artery (MMA) embolization performed as part of routine clinical care.